Tag: Lung Cancer

Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer

Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in… Continue reading Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer

Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer

Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in… Continue reading Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer

Adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations and cancer risk: A systematic review and meta‐analysis

A systematic review and meta-analysis of studies investigating associations between a score for adherence to the 2018 Cancer Prevention Recommendations and cancer risk was conducted . The summary risk ratio per 1-point increment in adherence score was 0.89 (95% CI) for breast cancer . There were no significant associations with prostate or other cancers .

Adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations and cancer risk: A systematic review and meta‐analysis

A systematic review and meta-analysis of studies investigating associations between a score for adherence to the 2018 Cancer Prevention Recommendations and cancer risk was conducted . The summary risk ratio per 1-point increment in adherence score was 0.89 (95% CI) for breast cancer . There were no significant associations with prostate or other cancers .

Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer

Pralsetinib showed robust and durable clinical activity with a well-tolerated safety profile in Chinese patients with RET fusion-positive non–small cell lung cancer (NSCLC) The most common grade 3/4 treatment-related adverse events in 68 patients were anemia (35.3%) and decreased neutrophil count (33.8%) As of March 4, 2022 (data cutoff), a confirmed objective response was observed… Continue reading Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer

Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer

Pralsetinib showed robust and durable clinical activity with a well-tolerated safety profile in Chinese patients with RET fusion-positive non–small cell lung cancer (NSCLC) The most common grade 3/4 treatment-related adverse events in 68 patients were anemia (35.3%) and decreased neutrophil count (33.8%) As of March 4, 2022 (data cutoff), a confirmed objective response was observed… Continue reading Efficacy and safety of pralsetinib in patients with advanced RET fusion‐positive non–small cell lung cancer

3 Questions: Sara Prescott on the brain-body connection

AI SummarySara Prescott, a faculty member in the Department of Biology at MIT, is researching the interoceptive nervous system and its role in detecting and responding to stimuli in the body. Her focus is on the mammalian airway and how neural pathways affect respiratory function and overall health. The goal of her research is to… Continue reading 3 Questions: Sara Prescott on the brain-body connection